Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Quigley Pharma, Inc.

Criteria

Inclusion Criteria:

• diagnosis of diabetic neuropathy

• must have some pain daily in the lower limbs due to diabetic polyneuropathy for at least 3 months prior to enrollment

• must be willing to comply with study directions, write information in a diary (such as pain medications taken), read and comprehend written instructions, complete questionnaires, and have the ability to apply the cream as directed

Exclusion Criteria:

• uncontrolled pain that has persisted for > 12 months.